1	Low linoleic acid foods with added DHA given to Malawian children with severe acute
2	malnutrition improves cognition: a randomized, triple blinded, controlled clinical trial
3	
4	Kevin Stephenson ¹ *, Meghan Callaghan-Gillespie ² *, Kenneth Maleta ³ , Minyanga Nkhoma ³ ,
5	Matthews George ³ , Hui Gyu Park ⁴ , Reginald Lee ² , Iona Humpheries-Cuff ⁵ , R J Scott Lacombe ⁴ ,
6	Donna R Wegner ² , Richard L Canfield ⁶ , J Thomas Brenna ^{4#} , Mark J Manary ^{2,3,7#}
7	
8	¹ Department of Medicine, Washington University, St. Louis, MO, ² Department of Pediatrics,
9	Washington University, St. Louis, MO, ³ Department of Public Health, School of Public Health &
10	Family Medicine, Kamuzu University of Health Sciences, Blantyre, ⁴ Department of Pediatrics,
11	University of Texas at Austin, Austin, Texas, ⁵ Project Peanut Butter, Lunzu, Malawi ⁶ Division
12	of Nutritional Sciences, Cornell University, Ithaca, NY. ⁷ United States Department of
13	Agriculture/Agricultural Research Service Children's Nutrition Research Center, Houston, TX.
14	*considered as first authors #considered as senior authors
15	
16	Authors last names: Stephenson, Callaghan-Gillespie, Maleta, Nkhoma, George, Park, Lee,
17	Humphries-Cuff, LaCombe, Wegner, Canfield, Brenna, Manary
18	Disclaimers: KS, MCG, KM, MN, MG, HGP, RL, IHC, DRW, JTB, RLC, RJSL, RC, MJM
19	have no conflict of interest to declare. MJM is an associate editor of AJCN.
20	Sources of support: Funding was generously provided by Unorthodox Philanthropy and Open
21	Philanthropy. Wiley Companies supported the work with a donation of ingredients for one of the
22	study foods.

- 23 Corresponding author: Mark Manary; Department of Pediatrics, Washington University, St.
- Louis, manarymj@wustl.edu; 314 454-2178.
- 25 Data Share Statement: Data described in the manuscript, code book, and analytic code will be
- 26 made available upon request pending application to the corresponding author and approval.
- 27 Running title: Low LA foods with DHA improve cognition in SAM
- 28 Abbreviations used: ALA, α-linolenic acid; DHA, docosahexaenoic acid; DHA-HO-RUTF,
- 29 high oleic acid RUTF with added DHA; EPA, eicosapentaenoic acid; HAZ, height-for-age z-
- 30 score; HO-RUTF, high oleic acid RUTF; LA, linoleic acid; MDAT, Malawi Developmental
- Assessment Tool; MUAC, mid-upper arm circumference; PSA, problems solving assessment;
- 32 PUFA, polyunsaturated fatty acid; RUTF, ready-to-use therapeutic food; SAM, severe acute
- 33 malnutrition; S-RUTF, standard RUTF; WHZ, weight-for-height z-score
- 34 **Trial registry:** NCT03094247, clinicaltrials.gov
- 35

3

36 Abstract

37 **Background:** There is concern that the PUFA composition of ready-to-use therapeutic food (RUTF) for treatment of severe acute malnutrition (SAM) is suboptimal for neurocognitive 38 39 recovery. **Objective:** We tested the hypothesis that RUTF made with reduced amounts of linoleic acid, 40 achieved using high oleic (HO) peanuts, with or without added DHA, improves cognition when 41 compared to standard RUTF (S-RUTF). 42 Methods: A triple-blind, randomized, controlled clinical feeding trial was conducted among 43 44 children with uncomplicated SAM in Malawi with 3 types of RUTF; DHA-HO-RUTF, HO-RUTF and S-RUTF. The primary outcomes, measured in a subset of subjects, were the Malawi 45 Developmental Assessment Tool (MDAT) global and 4 domain (gross motor, fine motor, 46 language and social) z-scores and a modified Willatts problem solving assessment (PSA) 47 intention score for 3 standardized problems, measured 6 months and immediately after 48 completing RUTF therapy, respectively. Plasma fatty acid content, anthropometry and eye 49 50 tracking were secondary outcomes. Comparisons were made between the novel PUFA RUTFs

51 and S-RUTF.

52 **Results:** Among the 2565 SAM children enrolled, global MDAT z-score was -0.69 ± 1.19 and -

53 0.88 ± 1.27 for children receiving DHA-HO-RUTF and S-RUTF, respectively (difference 0.19,

54 95% CI 0.01 to 0.38). The gross motor and social domains had higher z-scores among children

receiving either DHA-HO-RUTF than S-RUTF. The PSA problem 3 scores did not differ by

- dietary group (Odds ratio 0.92, 95% CI 0.67 to 1.26 for DHA-HO-RUTF). After 4 weeks of
- 57 treatment, plasma phospholipid EPA and α -linolenic acid were greater in children consuming

- 58 DHA-HO-RUTF or HO-RUTF when compared to S-RUTF (for all 4 comparisons P values <
- 59 0.001), but only plasma DHA was greater in DHA-HO-RUTF than S-RUTF (P < 0.001).
- 60 **Conclusions:** Treatment of uncomplicated SAM with DHA-HO-RUTF resulted in an improved
- 61 MDAT score, conferring a cognitive benefit six months after completing diet therapy. This
- 62 treatment should be explored in operational settings.
- 63
- 64 **Keywords:** severe acute malnutrition, ready-to-use therapeutic food, PUFA, cognition, MDAT,
- 65 DHA

5

66 Introduction

67 Severe acute malnutrition (SAM) is a global insult to the young child's developing mind and body. Therapeutic foods for SAM were largely designed to provide the nutrients known to affect 68 69 recovery of anthropometry and muscle mass (1). Vegetable oil rich, peanut-based ready-to-use therapeutic food (RUTF) is the standard of care for most SAM because it can be used safely at 70 71 home in the context of utmost poverty (2). It has been assumed that the brain and other viscera 72 would receive what is needed for recovery from standard RUTF (S-RUTF). Dietary omega-3 PUFAs are essential to normal brain development and function. Brain 73 74 accretion of the key neural structural component, omega-3 DHA, accelerates in the third trimester of gestation and continues until age 18 yr (3,4). Tissue DHA is derived from either 75 76 preformed dietary DHA or a precursor, typically plant-derived α -linolenic acid (ALA). ALA is less efficient in supplying brain DHA than dietary DHA (5). Omega-6 linoleic acid (LA) is 77 metabolized by the same desaturases (FADS2, FADS1) and elongases (ELOVL2, ELOVL5) as 78 79 omega-3 PUFA, and uses the same pathways to incorporate into membranes (6,7). LA intake 80 required to eliminate overt clinical abnormalities and support growth in infants is about 2% of energy or about 1% of fatty acids from diets deriving half their energy from fat (8). RUTF and 81 82 breastmilk are examples of such diets. Suppression of omega-3 PUFA tissue accretion by excess 83 dietary LA is an impactful clinical phenomenon (9). High LA dietary vegetable oils create a 84 metabolic demand for all omega-3 PUFA, thus requiring higher dietary DHA intake to produce 85 similar tissue DHA levels (10).

The development of peaceful and just citizens requires a high-level mental functioning to support executive problem solving and the affect regulation needed for resilient responses. Perinatal brain development depends on a balanced supply of brain specific nutrients.

6

89	Overwhelming amounts of LA in vegetable oils suppress trace amounts of ALA when the brain					
90	is rapidly accreting DHA. This inhibits neurobehavioral development at the levels of gene					
91	expression, hormonal balance, affect, and adaptive responses to environmental cues (11).					
92	Omega-3 deficient diets cause poor impulse control leading to potentiated stress response,					
93	increased depression and aggression, and poorer cognitive performance (12-14). Evidence-based					
94	guidelines include EPA and DHA supplements as a treatment for attention deficit hyperactivity					
95	disorder, autism spectrum disorder, and major depressive disorder (15,16).					
96	The potential effects of excess LA and limited ALA in RUTF on cognition have not been					
97	measured. Our previous study showed that RUTF with excess LA caused a 25% reduction in					
98	circulating DHA in 4 weeks (17). This clinical trial tested the hypothesis that RUTF made with					
99	reduced amounts of LA, achieved by using high oleic (HO) peanuts and palm oil (HO-RUTF)					
100	with or without added DHA (DHA-HO-RUTF), confers lasting cognition improvement when					
101	compared to S-RUTF. Cognition was measured by the Malawi Developmental Assessment Tool					
102	(MDAT), a standardized, validated battery of exercises, and a modified Willatts problem solving					
103	assessment (PSA) intention score.					
104 105 106	Methods					
107	Study design					
108	This triple-blind, randomized controlled clinical trial compared cognition in children					
109	treated for uncomplicated SAM receiving one of 3 RUTFs; HO-RUTF, DHA-HO-RUTF, or S-					

110 RUTF. The primary outcomes were the MDAT global z-score and PSA intention scores.

111 Secondary outcomes included MDAT domain z-scores, recovery rates, anthropometric growth

112 rates, Saccadic response time, visual paired comparison, novelty preference score, mean fixation

7

during familiarization, and adverse events. Detailed descriptions of the study methods areprovided in the study protocol available as supplementary material.

All sample size calculations were performed using $G^*Power (3.1.9.7)$ with two-tailed 115 116 testing at a significance level of 0.05 and power of 0.80 (18). A total of 300 children per group were required to detect a difference in MDAT global z-score of 0.25, assuming a SD of 1.1 (19-117 21). The difference of 0.25 z-scores was chosen based on prior nutrition-based effect sizes on 118 119 developmental scores as well as MDAT-specific changes seen in association with an illness (0.14 120 - 0.19) (22,23). Assuming a 25% loss to follow-up, 400 participants per group were designated 121 for testing. For the PSA, we assumed 20% of participants would not complete testing; thus, a 122 total of 300 children per group were needed to detect a standardized effect size of 0.25. This effect size was chosen based on previous studies of healthy infants under controlled conditions, 123 where standardized effects sizes ranged from 0.4-0.5 (24,25). Given the extended age range 124 125 relative to prior trials, the proximity of participants to SAM, and testing environs, we chose a 126 smaller effect size for sample size calculations. 127 The trial sample size was determined based on the key secondary outcome, recovery. A total of 900 participants per group was required to detect an improvement in recovery of 4% 128 129 assuming an expected recovery rate of 89% and default rate of 5%, both of which were determined based on prior operational experience in Malawi (26,27). 130

Participants were randomized individually in a 1:1:1 ratio into the three intervention groups. Computer-generated block randomization lists were created in blocks of 54 using six colors, two of which corresponded to each food. Participants were assigned to their food group when they drew an opaque envelope containing one of the colored cards.

8

Study foods were dispensed in identical packets with a colored sticker. The three study foods underwent extensive testing to minimize differences in appearance and taste. Excepting one remote member of the study team, all research personnel, including nurses, investigators, and laboratory personnel, were blinded to the color code. This unblinded individual did not evaluate any of the study subjects, nor did she analyze the primary outcomes. The trial is registered at clinicaltrials.gov as NCT03094247.

141

142 Subjects and setting

The trial was conducted at 28 clinics in rural Southern Malawi between October 2017 and December 2020. Most families in the study farm for subsistence, with corn as the staple crop.
Breastfeeding is ubiquitous throughout the first year of life. Homes are built from mud with thatch or corrugated metal sheet roofing. Plumbing and electricity are exceedingly rare, and water is obtained from boreholes, wells, or rivers.

Children aged 6-59 mo were eligible for enrollment if they had uncomplicated SAM, which was defined as a mid-upper arm circumference (MUAC) < 11.5 cm, and/or weight-forheight z-score < -3, and/or bilateral pitting edema, with an adequate appetite as determined by a 30g test feeding. Exclusion criteria included participation in a feeding program in the prior 1 month, presence of developmental delay, chronic debilitating medical condition, peanut allergy, or a hearing or vision problem.

The trial was approved by the Human Studies Committee of Washington University and the College of Medicine Research and Ethics Committee of the University of Malawi. Nurses fluent in Chichewa explained the trial to each child's caregiver and obtained verbal and written consent.

Participation

160	Upon enrollment, baseline demographic, socioeconomic, and health data were collected.				
161	Weight, length, and MUAC were measured. Caregivers received counseling, a two-week supply				
162	of RUTF, and a seven-day course of amoxicillin. Healthy twins of subjects were given an				
163	allotment of RUTF as well. Follow-up visits were scheduled at 2-week intervals, at which time				
164	anthropometric measurements were repeated and caregivers were asked about adherence and				
165	symptoms. Children were fed until reaching a clinical outcome or for a maximum of six bi-				
166	weekly follow-up visits. The anthropometry methods and definitions of the clinical outcomes are				
167	described in the study protocol.				
168	Beginning in February 2018, all participants under two years of age were assessed with a				
169	PSA within four weeks of their clinical outcome. Beginning in March 2018, all participants				
170	under 30 mo of age were asked to return to clinic 5 to 7 mo later for testing with the MDAT and				
171	Tobii X2-60 eye tracker eye-tracking testing.				
172	Children that either missed fortnightly assessments during therapeutic feeding or				
173	neurocognitive testing were sought on two extra occasions by health surveillance assistants and				
174	asked to return for the scheduled treatment or testing.				
175					
176	Study foods				
177	All three RUTF formulations were produced by Project Peanut Butter in Lunzu, Malawi,				
178	meeting all international quality and nutrient specifications. DHA-HO-RUTF and HO-RUTF				
179	were formulated to reduce LA and increase the omega-3 PUFA content (Table 1,				
180	Supplementary Tables 1-2, protocol section 6.5). Reductions in LA were achieved by using				

181	high oleic peanuts. Increases in omega-3 PLIFA were achieved by the addition of perilla oil				
101	high olect peanuts. Increases in onlega-51 OTA were achieved by the addition of perma on.				
182	DHA was enhanced in one of the RUTFs by the addition of encapsulated fish oil. The				
183	formulation was demonstrated to be acceptable in a pilot trial (17).				
184					
185	Neurocognitive testing				
186	MDAT has been validated within the study context (28). We performed MDAT				
187	assessments between five and seven months after a SAM outcome was reached to assess the				
188	effect of the RUTFs on neurodevelopment. No intervention was performed between the SAM				
189	outcome and the MDAT testing. MDAT contains 136 items across four domains, three of which				
190	are assessed by direct observation of the child (gross motor, fine motor, and language), while the				
191	fourth (social) is assessed via caregiver interview. These domain scores are then combined into a				
192	global score and compared to normal population reference values to provide age-adjusted z-				
193	scores (28). In line with prior protocols, failure of any six consecutive items resulted in failure of				
194	that domain and skipping to the subsequent domain (19). Global z-score outliers were defined				
195	after evaluation of the score distribution, and values < -5 were excluded.				
196	A modified version of the Willatts PSA was performed within four weeks of the outcome				
197	from treatment of SAM (24). This time point was chosen to detect the immediate effect of the				
198	intervention RUTFs. The assessment was modified to accommodate testing a wider age range				
199	than those used in prior studies and so contained three problems of increasing complexity (25).				
200	The goal of the assessment was to judge intentionality in means-end task completion. All				
201	assessments were video recorded for subsequent coding.				

Each problem contained a barrier between the child and the goal, a toy of her or his choosing. In problem 1, the toy was placed on a cloth and distanced from the child such that the

204	cloth had to be pulled by the child to reach the toy. In problem 2, the toy was covered with an
205	opaque cloth such that the child had to remove the cover to obtain the toy. Problem 3 was an
206	amalgam of problems 1 and 2, wherein the toy was placed on a cloth and under a cover, such that
207	the child had to pull the apparatus toward them and uncover the toy to obtain it.
208	Videos were coded using Behavioral Observation Research Interactive Software (29).
209	Coders were trained to achieve >.90 agreement by kappa statistic for intention scores on a
210	random sample of 20 test videos before coding for the trial. High reliability was maintained
211	throughout the coding period by double-coding >50% of videos followed by a joint resolution of
212	discrepancies. In a modification of the procedure of Willatts et al problem solving behaviors,
213	problems were coded for two primary components, each on a scale of 0-2 and each assessing an
214	aspect of intentionality: attentional orienting to each problem subgoal and the execution of
215	behaviors on each subgoal. Problems 1 and 2 were scored 0-4, while problem 3 had two subgoals
216	(moving cloth and removing the cover) and thus was scored 0-8. "No score" was a possible
217	outcome for all problems, and reasons for this result were recorded.
218	Two eye-tracking tests were performed as secondary cognitive outcomes: a visual paired
219	comparison task, and the infant orienting with attention task. Identical procedures to those
220	previously described were used (20). The visual paired task consisted of 4 trials of African faces.
221	The infant orienting task measured saccadic reaction time in a standardized manner. The testing
222	sequence for paired comparison task and orienting attention task was randomized.
223	All neurocognitive assessors underwent extensive training and were required to pass
224	periodic evaluations before administering the tests and throughout the trial. Please see the study
225	protocol for further details.
226	

12

227 Plasma sampling and analysis

228 The purpose of blood sampling was to characterize the concentrations of fatty acids in the study groups, thus only a subset of children were sampled. Blood collection and analysis followed best 229 230 practices (30). After receiving 4 weeks of RUTF, blood was collected by venipuncture and 231 placed in an ethylenediaminetetraacetic acid tube. Plasma was then separated from red cells and 232 held at -20°C until transferred to the laboratories of JT Brenna at the Dell Pediatric Research 233 Institute in Austin, TX. Plasma phospholipids were chosen as the preferred lipid pool because 234 they respond in a matter of weeks to changes in the diet compared to months for red blood cells, 235 but are stable to fatty acids from recent meals which are largely triacylglycerols. Red blood cells 236 PUFA also degrade at -20°C by peroxidation catalyzed by iron release from ruptured cells (30). 237 For analyses, plasma phospholipids were isolated using an automated three-phase liquid-238 liquid extraction method (31). Samples were then transmethylated to generate fatty acid methyl esters according to our routine methods (32). These fatty acid derivatives were detected and 239 240 quantified by gas chromatography (GC)-flame ionization detection and structure confirmed by a 241 specialized GC tandem mass spectrometry method. Quantitative standards of 25 fatty acid methyl esters were then used to quantify the amounts of each detected. Results are reported as a 242 weight percentage of total fatty acid identified. These methods are carefully detailed in the study 243 244 protocol.

245

246 Statistical analysis

Analysis were performed by a blinded investigator using a modified intention to treat
methodology wherein children who were discovered not to meet enrollment criteria were
excluded from analysis. Baseline characteristics were summarized as means ± SD, medians

13

250	(IQR), or percentages. Anthropometric indices were calculated with WHO Anthro version 3.1
251	(WHO). Rates of weight, MUAC, and length gain were calculated over the entire period of
252	feeding.
253	Outcomes from the DHA-HO-RUTF and HO-RUTF groups were compared to S-RUTF.
254	Continuous outcomes were compared using Student's t-test. Categorical outcomes were
255	compared using the chi-square test. PSA scores were analyzed using ordinal logistic regression
256	with age as a covariate. An interaction term between intervention group and age was offered into
257	the model but was not significant for any problem and thus was not included in the final model.
258	The proportional odds assumption was assessed graphically and deemed not violated by
259	producing a series of binary logistic regressions at cut-points for all outcome values > 2.
260	Significance testing was restricted to pairwise comparisons of the two primary outcomes and key
261	secondary outcomes, namely the domain MDAT z-scores and recovery rates. In all other cases,
262	differences with unadjusted 95% CIs were calculated and reported. Analysis was completed
263	using R version 4.0.1 (R Foundation for Statistical Computing) and SPSS version 27 (SPSS Inc.)
264	(33).

265

266 **Results**

Of the 2758 children with SAM identified between October 2017 and December 2020, 2565
children were included in the study (Figure 1). In 2020, there were three stock-outs of RUTFs
due to ingredient importation restrictions related to the COVID-19 pandemic. This precluded
randomization as it was designed, and so subjects were randomized among the available RUTFs.
This is described in the study protocol available as supplementary material. Baseline

272	characteristics were similar among the three groups, both in the entire study sample and within				
273	the MDAT and problem solving assessment subgroups (Table 2, Supplementary Tables 3-4).				
274	Children receiving DHA-HO-RUTF had higher MDAT global, gross motor, and social z-				
275	scores than those receiving S-RUTF, while children receiving HO-RUTF had higher social z-				
276	scores than those receiving S-RUTF at about 6 months post SAM outcome (Table 3,				
277	Supplementary Table 3). Probability density distributions for global and domain MDAT z-				
278	scores for each group are shown in Figure 2, while means are shown in Supplementary Figure				
279	1. When stratified by age, the probability density distributions of global MDAT z-score show				
280	that children <12 mo at the time of SAM resemble healthy children, while children >18 mo at the				
281	time of SAM display scores approximately-2 z-scores worse. (Supplementary Figure 2).				
282	HO-RUTF or DHA-HO-RUTF did not lead to superior PSA scores compared to S-RUTF				
283	(Table 3, Figure 3). Inability to participate in problem 3 adequately to obtain a score occurred				
284	more often than anticipated, and resulted in an underpowered analysis for PSA. Predicted				
285	probabilities from the ordinal logistic regression model showed that intention scores were				
286	strongly influenced by age and varied most in problem 3 (Supplementary Figure 3).				
287	Neither intervention RUTF led to superior eye-tracking results, anthropometric recovery,				
288	rates of gain in weight, length, or MUAC compared to S-RUTF (Table 3). Potential adverse				
289	events, including reports of fever, diarrhea, food intolerance, and poor appetite, were not higher				
290	in the intervention groups compared to S-RUTF, nor were default rates different between groups				
291	(Table 3).				
292	Summary statistics for enrollment characteristics and analysis of primary and key				
293	secondary outcomes were repeated after excluding those children enrolled during each of the				
294	three stock-out periods (271 children excluded, Supplementary Tables 5-6). The groups				

295	remained balanced at baseline and the point estimates were similar for all primary and secondary				
296	outcomes. Exploratory analysis of MDAT results by key subgroups is shown in Supplementary				
297	Figure 4. Linear and ordinal logistic regression models assessed the effects of DHA and HO in				
298	RUTF on MDAT global z-score and PSA intentions scores, respectively, is shown in				
299	Supplementary Table 7.				
300	Six key plasma PUFA concentrations were selected to describe the biochemical changes				
301	induced by HO-RUTF and DHA-HO-RUTF (Figure 4). LA and ALA are the primary dietary				
302	omega-6 and omega-3 fatty acids respectively, EPA and DHA are bioactive omega-3 fatty acids				
303	that affect mood and cognition, and arachidonic acid and docosapentaenoic acid are bioactive				
304	omega-6 fatty acids. Consumption of HO-RUTF and DHA-HO-RUTF resulted in greater				
305	amounts of plasma ALA, as well as more EPA, while DHA was increased only in the DHA-HO-				
306	RUTF group. S-RUTF resulted in more LA than DHA-HO-RUTF, as well as greater amounts of				
307	the bioactive omega-6 fatty acids. The full plasma fatty acid concentrations from SAM children				
308	fed different RUTFs can be found in Supplementary Table 8.				
309					
310	Discussion				
311	This trial found that SAM children who consumed DHA-HO-RUTF achieved superior global				
312	MDAT scores than children who consumed S-RUTF. DHA-HO-RUTF caused a positive shift in				
313	the distribution of MDAT scores measured about 6 months after a SAM outcome with no				
314	intervening experimental treatment. However, PSA scores were similar in all dietary groups. The				
315	expected improvements in plasma fatty acid content were observed; children receiving DHA-				
316	HO-RUTF had greater concentrations of DHA. Anthropometric recovery was similar; 72% for				

16

317 DHA-HO-RUTF and 75% for S-RUTF. No adverse effects or negative preferences against
318 DHA-HO-RUTF were observed in this large trial.

319 This trial demonstrated a clear discrepancy between anthropometric recovery and 320 cognitive recovery in SAM. Children fed S-RUTF show inferior cognitive performance when compared with population norms, an insult of 0.9 MDAT z-scores. This deleterious effect is 321 observed in all domains of the MDAT, except for the social domain. The magnitude of the insult 322 suggests that a frameshift in thinking and approach may be warranted with respect to SAM 323 324 treatment and recovery. The focus on cognitive recovery must rise to equal importance as 325 anthropometric recovery to enable the child to thrive. The distribution of MDAT scores in children < 1 year of age mirrors a healthy population (Supplementary Figure 2) and offers hope 326 that improvements in treatment may avert lifelong disabilities. The increase seen in MDAT by 327 328 the inclusion of less LA and more DHA in RUTF is encouraging and actionable. Differences seen between dietary groups were not dramatic (Supplemental Figure 1) when compared to the 329 330 SAM insult. Our results report a functional benefit that extends the importance of our previous 331 biochemical results, indicating that children recovering from SAM require a source of DHA to restore cognition (17,34). 332

The MDAT was developed in a rural Malawian setting, is fully validated, reliable, and predictive of later intellectual performance. This is why MDAT was chosen was as a primary outcome, and why Malawi was chosen as the study location. MDAT has revealed cognitive deficits in acutely malnourished populations in Malawi and Burkina Faso. In a previous study, MDAT domain scores were reported in 150 Malawian SAM children upon discharge from the hospital (21). All 4 domain scores were remarkably lower among hospitalized SAM children than in our population; differences of -1.7 z-scores seen in gross motor, -1.0 z-scores in fine

340	motor, -0.7 in language, and -3.0 z-scores seen in social. The MUAC of these hospitalized
341	children was 11.5 cm, similar to that in our population, although the clinical status due to
342	infectious complications was likely worse. These findings lead us to speculate that significant
343	improvements in MDAT occur after discharge, especially in the gross motor and social domains,
344	and that maximizing this "cognitive recovery" should be a primary goal in malnutrition programs
345	The PSA scores did not differ between food groups. PSA problem 3 has been used to
346	demonstrate cognitive differences among healthy infants aged 9-12 mo receiving DHA enriched
347	infant formulas (25). In this study, half of the healthy infants achieved a perfect score on the PSA
348	on all 3 attempts. This is in contrast to our results, wherein only 15% of children achieved a
349	perfect score on any attempt. This suggests the presence of a substantial cognitive deficit at the
350	time of anthropometric recovery. Our PSA was conducted using this very same problem and
351	protocol, and with a sample size increased three-fold, as previously reported, so it is unlikely the
352	failure to detect differences is the result of methodological flaws. Rather, PSA problem 3 was
353	beyond the intellectual capacity of most children tested. Subsequent use of PSA in SAM should
354	explore its timing relative to anthropometry and the potential utility of repeated testing.
355	Two previous, smaller studies in SAM children were done using blood measures of fatty
356	acid content (18,35). Our findings are consonant with these; increases in DHA were only seen
357	when fish oil was added to the diet, and reduction in dietary LA resulted in greater EPA content.
358	The food formulations of HO-RUTF and DHA-HO-RUTF were achieved by Project
359	Peanut Butter by ingredient changes, without alterations in the mixing or packaging processes.
360	HO peanuts can be purchased in the major peanut production markets worldwide. DHA is now
361	encapsulated and available from the same ingredient producers as the micronutrient premix.
362	Encapsulation is very durable and obscures the taste of the fish oil exceedingly well, in addition

363	to limiting oxidative degradation. Non-genetically modified, high oleic vegetable oils are
364	available at a cost of about 10% more than traditional vegetable oils. They were developed for
365	purposes of increasing the shelf-life of the oil and have been shown to have a reduced risk of
366	heart disease in adults.
367	Our study has multiple limitations. The study population did not habitually consume fish,
368	and the positive effect of DHA-HO-RUTF in a fish consuming population might differ.
369	However, most children recovering from SAM worldwide consume little else but RUTF, and
370	RUTF should meet the needs of such children. Our study population developed SAM largely
371	because of food insecurity. Children in whom chronic illness or excessive inflammation
372	precipitated SAM might not realize similar cognitive benefits of DHA-HO-RUTF. The use of
373	different cognitive assessments at single time points limited the ability to interpret the dynamic
374	nature of cognitive recovery. Food stock-outs resulted in imbalanced randomization, potentially
375	introducing bias. Re-analysis of the sample enrolled outside of these stock-outs did not show
376	evidence of bias.
377	We estimate that during treatment, SAM children were consuming about 240g RUTF/d.
378	For the DHA-HO-RUTF group, DHA intake averaged 173 mg/d or about 0.24% w/w DHA. The
379	global breastmilk DHA reference level is 0.32% w/w.(35) Fat constitutes half the energy in
380	breastmilk and RUTF. The DHA content of DHA-HO-RUTF and breastmilk was similar.
381	Importantly, the effective intervention was to supply RUTF with DHA and with limited LA
382	when recovery food was supplying calories and protein needed to restart a normal or even
383	accelerated trajectory of neurocognitive development. The brain substitutes omega-6
384	docosapentaenoic acid (DPA6) for DHA when dietary LA is surfeit and omega-3 is limiting.

19

385 DPA does not support neurocognitive function similarly to DHA, thus our results may point to 386 slow replacement of DHA for DPA in the months after recovery (11).

387	LA antagonism of omega-3 PUFAs is understood from a molecular and genetic basis (36-
388	38). Large dietary amounts of LA and little ALA given to pregnant animals results in offspring
389	with increased aggression and impulsivity, reduced executive function, and impaired visual
390	function (39). Confusion over the interrelationship of dietary LA and ALA has led to futile
391	attempts to increase circulating/tissue DHA by increasing dietary ALA without reducing LA.
392	While the dietary omega-6 to omega-3 ratio, usually cast as [LA]/[ALA], is widely quoted as a
393	parameter defining omega-3 tissue accretion, it is the excess of omega-6 over omega-3, i.e. [LA]-
394	[ALA], that controls DHA availability (40,41). Clinical studies show that additional ALA does
395	not increase circulating or breastmilk DHA (42). Moreover, no amount of supplementary omega-
396	3 EPA increases DHA. To increase DHA, two dietary interventions are well established:
397	lowering dietary LA and increasing dietary DHA.

This study is the first to provide direct evidence that reduction in LA and addition of 398 399 DHA in RUTF enhances cognition in SAM children. This finding is consonant with a body of scientific evidence that extends over many decades, methodologies, and species. Perhaps the 400 401 most compelling evidence is found in the composition of breast milk. The need to enhance 402 cognitive recovery in SAM is substantial, even crucial, as this insult affects tens of millions of children worldwide annually. At present, about 85M children worldwide will develop SAM in 403 404 the first 5 years of their life, a number roughly equal to the estimate of all other causes of childhood developmental delay. Changing the composition of RUTF to reduce the insult of SAM 405 is safe, feasible, and effective. Further research is needed to optimize the amount and duration of 406 DHA supplementation, but in the meantime, there is a clear course of action to help SAM 407

20

408 children worldwide: require that RUTF have reduced amounts of LA and include preformed409 DHA.

410

411 Acknowledgment

- 412 MJM is an associate editor at AJCN. The other authors have no conflict of interest to declare.
- 413 JTB, MCG, KM, DRW, RC, and MJM designed the research; RC and KM designed the
- 414 neurocognitive testing and scoring; MN, MG, RL, IHC, KM, and MCG conducted the clinical
- research, assessed the children's cognition, and collected the samples; JTB, HGP, and RJSL
- 416 conducted the basic laboratory work, KS, MCG, JTB, RJSL, RC, and MJM analyzed and
- 417 interpreted the data; KS and MCG created the figures and graphically analyzed the data; MCG,
- 418 KS, and MJM wrote the first draft of the manuscript with input from JTB; MJM has primary
- responsibility for final content. All authors read and approved the final manuscript. The trial was
- 420 registered at NCT03094247.
- 421
- 422 We are grateful to the Wiley Companies for the generous gift of AlaskOmega® omega-3

423 concentrate derived from Alaskan Pollock (Gadus chalcogrammus).

References

1. Chase RP, Kerac M, Grant A, Manary M, Briend A, Opondo C, Bailey J. Acute malnutrition recovery energy requirements based on mid-upper arm circumference : secondary analysis of feeding program data from 5 countries, combined protocol for acute malnutrition study (ComPAS) stage 1. PLoS ONE 2020;15: e0230452.

2. World Health Organization, the World Food Programme, the United Nations System Standing Committee on Nutrition and the United Nations Children's Fund . Community-based management of severe acute malnutrition. 2007 accessed July 2021 https://www.who.int/publications/i/item/9789280641479

3. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992;120(4 Pt 2):S129-38.

 Carver JD, Benford VJ, Han B, Cantor AB. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull 2001;56(2):79-85. doi: 10.1016/s0361-9230(01)00551-2 [published Online First: 2001/11/13]

5. Lacombe RJS, Chouinard-Watkins R, Bazinet RP. Brain docosahexaenoic acid uptake and metabolism. Mol Aspects Med 2018;64:109-34.

6. Lattka E, Illig, Koletzko B, Heinrich J. Genetic variants of the FADS1 FADS2 gene cluster as related to fatty acid metabolism. Curr Opin Lipdol 2010;21:64-9.

7. Zhang JY, Kothapalli K, Brenna JT. Desaturase and elongase-limiting endogenous long-chain polunsaturated fatty acid biosynthesis. Curr Opin Clin Nutr Metabol Care 2016;19:103-10.

8.. Holman RT, Caster WO, Wiese HF. The Essential Fatty Acid Requirement of Infants and the Assessment of Their Dietary Intake of Linoleate by Serum Fatty Acid Analysis. Am J Clin Nutr 1964;14:70-5. doi: 10.1093/ajcn/14.2.70 [published Online First: 1964/02/01]

9. Holman RT. The slow discovery of the importance of omega 3 essential fatty acids in human health. J Nutr 1998;128(2 Suppl):427S-33S.

10. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WEM. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006;83(6 Suppl):1483S-93S. doi: 10.1093/ajcn/83.6.1483S [published Online First: 2006/07/18]

11. Brenna JT. Animal studies of the functional consequences of suboptimal polyunsaturated fatty acid status during pregnancy, lactation and early post-natal life. Matern Child Nutr 2011;7 Suppl 2:59-79. doi: 10.1111/j.1740-8709.2011.00301.x

12. Mathieu G, Denis S, Lavialle M, Vancassel S. Synergistic effects of stress and omega-3 fatty acid deprivation on emotional response and brain lipid composition in adult rats. Prostaglandins Leukot Essent Fatty Acids 2008;78(6):391-401. doi: 10.1016/j.plefa.2008.05.003 [published Online First: 2008/06/27]

 DeMar JC, Jr., Ma K, Bell JM, Igarashi M, Greenstein D, Rapoport SI.. One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats. J Lipid Res 2006;47(1):172-80. doi: 10.1194/jlr.M500362-JLR200 [published Online First: 2005/10/08]

14. Hafandi A, Begg DP, Premaratna SD, Sinclair AJ, Jois M, Weisinger RS.. Dietary repletion with omega3 fatty acid or with COX inhibition reverses cognitive effects in F3 omega3 fatty-acid-deficient mice. Comp Med 2014;64(2):106-9. [published Online First: 2014/03/29]

23

15. Chang JP, Su KP. Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence-Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. Clin Psychopharmacol Neurosci 2020;18(4):469-83. doi: 10.9758/cpn.2020.18.4.469 [published Online First: 2020/10/31]

16. Hallahan B, Ryan T, Hibbeln JR, Murray IT, Glynn S, Ramsden CE, SanGiovanni JP, et al.
Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J
Psychiatry 2016;209(3):192-201. doi: 10.1192/bjp.bp.114.160242 [published Online First:
2016/04/23]

17. Hsieh JC, Liu L, Zeilani M, Ickes S, Trehan I, Maleta K, Craig C, et al. High-Oleic Readyto-Use Therapeutic Food Maintains Docosahexaenoic Acid Status in Severe Malnutrition. J Pediatr Gastroenterol Nutr 2015;61(1):138-43. doi: 10.1097/MPG.000000000000741

18. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1:
tests for correlation and regression analyses. Behav Res Methods 2009;41(4):1149-60. doi:
10.3758/BRM.41.4.1149 [published Online First: 2009/11/10]

19. Olsen MF, Iuel-Brockdorff AS, Yaméogo CW, Chicon B, Fabiansen C, Filteau D, Phelan K, et al. Impact of food supplements on early child development in children with moderate acute malnutrition: A randomised 2 x 2 x 3 factorial trial in Burkina Faso. PLoS Med 2020;17(12):e1003442. doi: 10.1371/journal.pmed.1003442 [published Online First: 2020/12/23]

20. Prado EL, Maleta K, Caswell BL, George M, Oakes LM, DeBolt MC, Bragg MG, et al. Early Child Development Outcomes of a Randomized Trial Providing 1 Egg Per Day to Children Age 6 to 15 Months in Malawi. The Journal of Nutrition 2020;150(7):1933-42. doi:

10.1093/jn/nxaa088

24

21. van den Heuvel M, Voskuijl W, Chidzalo K, Kerac M, Reijneveld SA, Bandsma R, Gladstone M.. Developmental and behavioural problems in children with severe acute malnutrition in Malawi: A cross-sectional study. J Glob Health 2017;7(2):020416. doi: 10.7189/jogh.07.020416

22. Larson LM, Yousafzai AK. A meta analysis of nutrition interventions on mental development of children under two in low and middle income countries. Maternal & Child Nutrition 2017;13(1):e12229. doi: 10.1111/mcn.12229

23. Olsen MF, Iuel-Brockdorff AS, Yaméogo CW, Chicon B, Fabiansen C, Filteau D, Phelan K et al. Early development in children with moderate acute malnutrition: A cross-sectional study in Burkina Faso. Matern Child Nutr 2020;16(2):e12928. doi: 10.1111/mcn.12928 [published Online First: 2019/12/11]

24. Willatts P, Forsyth JS, DiModugno MK, Varma S, Colvin M. Influence of long-chain polyunsaturated fatty acids on infant cognitive function. Lipids 1998;33(10):973-80. doi: 10.1007/s11745-998-0294-7

25. Drover J, Hoffman DR, Castañeda YS, Morale SE, Birch EE. Three Randomized Controlled Trials of Early Long-Chain Polyunsaturated Fatty Acid Supplementation on Means-End Problem Solving in 9-Month-Olds. Child Development 2009;80(5):1376-84. doi: 10.1111/j.1467-8624.2009.01339.x

26. Trehan I, Goldbach HS, Lagrone LN, Meuli GJ, Wang RJ, Maleta KM, Manary MJ. Antibiotics as Part of the Management of Severe Acute Malnutrition. New England Journal of Medicine 2013;368(5):425-35. doi: 10.1056/nejmoa1202851

27. Linneman Z, Matilsky D, Ndekha M, Manary MJ, Maleta K, Manary MJ. A large-scale operational study of home-based therapy with ready-to-use therapeutic food in childhood malnutrition in Malawi. Maternal & Child Nutrition 2007;3(3):206-15. doi: 10.1111/j.1740-8709.2007.00095.x

28. Gladstone M, Lancaster GA, Umar E, Nyirenda M, Kayira E, van den Broek N, Smyth RL.. The Malawi Developmental Assessment Tool (MDAT): the creation, validation, and reliability of a tool to assess child development in rural African settings. PLoS Med 2010;7(5):e1000273. doi: 10.1371/journal.pmed.1000273 [published Online First: 2010/05/25]

29. Friard O, Gamba M. BORIS: a free, versatile open-source event-logging software for video/audio coding and live observations. Methods in Ecology and Evolution 2016;7(11):1325-30. doi: <u>https://doi.org/10.1111/2041-210X.12584</u>

30. Brenna JT, Plourde M, Stark KD, et al. Best practices for the design, laboratory analysis, and reporting of trials involving fatty acids. Am J Clin Nutr 2018;108(2):211-27. doi: 10.1093/ajcn/nqy089 [published Online First: 2018/06/23]

31. A robotic system for high throughput isolation of phospholipids from non-polar lipids. The67th ASMS Annual Conference on Mass Spectrometry and Allied Topics; 2019; Atlanta,Georgia.

32. Zhou Y, Nijland M, Miller M, et al. The influence of maternal early to mid-gestation nutrient restriction on long chain polyunsaturated fatty acids in fetal sheep. Lipids 2008;43(6):525-31. doi: 10.1007/s11745-008-3186-1 [published Online First: 2008/05/16]

33. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [program], 2017.

26

34. Jones KD, Ali R, Khasira MA, Odera D, West AL, Koster G, Akomo P, et al. Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial. BMC Med. 2015;13(1):93. doi: 10.1186/s12916-015-0315-6.

35. Brenna JT, Varamini B, Jensen RG, et al. Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. Am J Clin Nutr 2007;85(6):1457-64.

36. Kothapalli KSD, Park HG, Brenna JT. Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19(,, bigstar, bigstar bigstar). Prostaglandins Leukot Essent Fatty Acids 2020;162:102183. doi: 10.1016/j.plefa.2020.102183 [published Online First: 2020/10/11]

37. Koletzko B, Reischl E, Tanjung C, et al. FADS1 and FADS2 Polymorphisms Modulate Fatty
Acid Metabolism and Dietary Impact on Health. Annual review of nutrition 2019;39:21-44. doi:
10.1146/annurev-nutr-082018-124250 [published Online First: 2019/08/23]

38. Reynolds LM, Howard TD, Ruczinski I, et al. Tissue-specific impact of FADS cluster variants on FADS1 and FADS2 gene expression. PLoS One 2018;13(3):e0194610. doi:
10.1371/journal.pone.0194610 [published Online First: 2018/03/29]

39. Anderson GJ, Neuringer M, Lin DS, et al. Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys. Pediatr Res 2005;58(5):865-72. doi: 10.1203/01.pdr.0000182188.31596.5a [published Online First: 2005/11/01]

40. Gibson RA, Neumann MA, Lien EL, et al. Docosahexaenoic acid synthesis from alphalinolenic acid is inhibited by diets high in polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2013;88(1):139-46. doi: 10.1016/j.plefa.2012.04.003

41. Brenna JT, Salem N, Jr., Sinclair AJ, et al. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 2009;80(2-3):85-91. doi: S0952-3278(09)00016-7 [pii]

10.1016/j.plefa.2009.01.004 [published Online First: 2009/03/10]

42. Francois CA, Connor SL, Bolewicz LC, et al. Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am J Clin Nutr 2003;77(1):226-33. doi: 10.1093/ajcn/77.1.226 [published Online First: 2002/12/25]

28

Table 1. Composition of study ready-to-use therapeutic foods ¹			
	DHA-HO-RUTF	HO-RUTF	S-RUTF
Ingredient			
Milk powder, non-fat, dry, g	22.0	22.0	27.3
Milk, sweet whey powder, g	6.1	6.1	0.0
Palm oil, g	14.0	14.0	16.0
Canola oil, g	0.0	0.0	5.1
Sugar, g	24.5	26.0	23.0
High oleic peanuts, g	25.0	25.0	0.0
Standard, high omega6 peanuts, g	0.0	0.0	23.7
Perilla oil, g	3.0	3.0	0.0
Hydrogenated vegetable $\operatorname{oil}^{\dagger}$, g	1.0	1.0	2.0
Micronutrient powder, g	2.9	2.9	2.9
DHA, g	1.5	0.0	0.0
Macronutrient			
Energy, kcal	532.0	531.0	541.0
Protein, g	15.2	15.2	15.7
Protein, dairy, g	8.9	8.9	9.8
Lipids, g	30.2	29.5	32.7
Omega-6 polyunsaturated fatty acids, g	2.2	2.1	5.8
Omega-3 polyunsaturated fatty acids, g	1.5	1.4	0.5
DHA, mg	72.0	0.0	0.0
EPA, mg	14.0	0.0	0.0

1

¹Content expressed in per 100g. DHA, docosahexaenoic acid; DHA-HO-RUTF,

docosahexaenoic acid added to RUTF made with high oleic acid peanuts; EPA, eicosapentaenoic acid; HO-RUTF, RUTF made with high oleic acid peanuts; RUTF, ready-to-use therapeutic food; S-RUTF, standard RUTF.

[†]This was a proprietary commercial product, Trancendim 180 (Caravan Foods)

29

Table 2. Baseline characteristics of Malawian children receiving study foods¹

	DHA-HO-RUTF	HO-RUTF	S-RUTF
	(N = 809)	(N = 860)	(N = 896)
Female sex, no. (%)	452 (55.9)	469 (54.5)	527 (58.8)
Age, mo., median (IQR)	12.1 (7.9 - 20.4)	12.2 (7.8 - 21.2)	12.7 (8.1 - 21.5)
Edematous, no. (%)	274 (33.9)	302 (35.1)	293 (32.7)
Mid-upper-arm circumference, cm	11.6 ± 1.2	11.6 ± 1.2	11.6 ± 1.1
MUAC < 11.5 cm, no. (%)	534 (66)	545 (63.4)	600 (67)
Weight-for-height z-score	-1.9 ± 1.2	-1.9 ± 1.2	-2.0 ± 1.2
WHZ \leq -3, no. (%)	167 (20.6)	181 (21.0)	186 (20.8)
Height-for-age z-score	-3.3 ± 1.5	-3.3 ± 1.4	-3.2 ± 1.4
HAZ \leq -2, no./total no. (%)	667/808 (82.5)	726/858 (84.6)	746/896 (83.3)
Fever in past 2 weeks, no./total no. (%)	461/805 (57.3)	518/857 (60.4)	554/893 (62.0)
Diarrhea in past 2 weeks, no./total no. (%)	446/805 (55.4)	474/858 (55.2)	484/891 (54.3)
Child breastfed, no./total no. (%)	520/808 (64.4)	565/858 (65.9)	575/893 (64.4)
HIV-seropositive, no./total no. tested (%)	19/265 (7.2)	25/301 (8.3)	23/311 (7.4)
Mother alive, no./total no. (%)	783/807 (97)	827/860 (96.2)	876/895 (97.9)
Number of siblings, median (IQR)	2 (0-3)	2 (1-3)	2 (0-3)
Thatch roof, no./total no. (%)	607/803 (75.6)	659/859 (76.7)	689/890 (77.4)
Radio in home, no./total no. (%)	178/807 (22.1)	196/854 (23.0)	168/893 (18.8)
Clean water source, no./total no. (%)	761/807 (94.3)	795/857 (92.8)	834/895 (93.2)

¹Plus-minus values are means ± SD. ART, antiretroviral therapy; DHA-HO-RUTF, docosahexaenoic acid added to ready-to-use therapeutic food made with high-oleic acid peanuts; HAZ, height-for-age z-score; HIV, human immunodeficiency virus; HO-RUTF, RUTF with high oleic acid peanuts; IQR, interquartile range; MUAC, mid-upper arm circumference; WHZ, weight-for-height z-score.

30

Table 3. Outcomes and adverse events, according to intervention group¹

	DH	A-HO-RUTF	I	HO-RUTF		S-RUTF	DHA-HO-RUTF vs. S-RUTF	HO-RUTF vs. S-RUTF
	Ν		Ν		Ν		Comparison†	Comparison [†]
Cognitive Outcomes								
Malawi Developmental								
Global	332	$\textbf{-0.69} \pm 1.19$	312	$\textbf{-0.80} \pm 1.25$	342	$\textbf{-0.88} \pm 1.27$	0.19 (0.01 to 0.38) ^a	0.08 (-0.11 to27)
Gross motor domain	331	$\textbf{-1.08} \pm 1.66$	312	-1.34 ± 1.67	342	$\textbf{-1.37} \pm 1.78$	0.29 (0.03 to 0.55) ^b	0.02 (-0.24 to 0.29)
Fine motor domain	323	$\textbf{-1.81} \pm 1.71$	306	$\textbf{-1.83} \pm 1.80$	337	$\textbf{-1.91} \pm 1.83$	0.14 (-0.17 to 0.37)	0.07 (-0.21 to 0.35)
Language domain	331	$\textbf{-0.73} \pm 1.35$	312	$\textbf{-0.93} \pm 1.51$	342	$\textbf{-0.90} \pm 1.41$	0.17 (-0.04 to 0.38)	-0.03 (-0.25 to 0.19)
Social domain	332	0.40 ± 1.01	311	0.49 ± 1.00	342	0.24 ± 1.04	0.16 (0.00 to 0.31) $^{\rm c}$	0.24 (0.09 to 0.40) $^{\rm d}$
Problem Solving Assessment								
Problem 1, no. (%) with perfect score	298	90 (30)	281	88 (31)	292	90(31)	0.99 (0.66 to 1.19) ‡	0.89 (0.74 to 1.31) ‡
Problem 2, no. (%) with	293	169 (58)	283	151 (53)	294	168 (57)	0.97 (0.71 to 1.33) ‡	0.88 (0.64 to 1.21) ‡
perfect score Problem 3, no. (%) with perfect score	236	50 (21)	241	54 (22)	238	51 (21)	0.92 (0.67 to 1.26) ‡	1.01 (0.74 to 1.38) ‡
Eye-tracking Infant Oriented with Attention response time,	217	430 ± 106	223	431 ± 106	254	418 ± 96	12 (-10 to 34)	13 (-9 to 36)
Visual paired comparison	239	0.60 ± 0.1	238	0.58 ± 0.1	290	0.59 ± 0.1	0.01 (-0.01 to 0.03)	-0.01 (-0.03 to 0.01)
novelty preference score Mean fixation duration,	248	330 ± 152	244	358 ± 154	297	343 ± 162	-13 (-45 to 19)	15 (-17 to 47)
Programmatic Outcomes								
Recovered, no. (%)	809	583 (72.1)	860	638 (74.2)	896	672 (75.0)	-2.9 (-7.1 to 1.3)	-0.8 (-4.9 to 3.3)
Remained malnourished, no. (%)	809	164 (20.3)	860	162 (18.8)	896	172 (19.2)	1.1 (-2.7 to 4.9)	-0.4 (-4.1 to 3.3)
Improved to moderate	809	119 (14.7)	860	114 (13.3)	896	117 (13.1)	1.6 (-1.7 to 4.9)	0.2 (-3.0 to 3.4)
Remained severely malnourished, no. (%)	809	45 (5.6)	860	48 (5.6)	896	55 (6.1)	1.1 (-2.7 to 1.7)	-0.5 (-2.7 to 1.7)
Died, no. (%)	809	19 (2.3)	860	16 (1.9)	896	13 (1.5)	0.8 (-0.5 to 2.1)	0.4 (-0.8 to 1.6)
Defaulted, no. (%)	809	43 (5.3)	860	44 (5.1)	896	39 (4.4)	0.9 (-1.1 to 2.9)	0.7 (-0.13 to 2.7)
Anthropometric Outcomes								
Rate of weight gain,	786	3.7 ± 4.0	836	3.8 ± 3.8	875	4.1 ± 3.6	-0.3 (-0.7 to 0.0)	-0.3 (-0.6 to 0.1)
Rate of mid-upper arm circumference gain, mm/day	786	0.27 ± 0.27	836	0.26 ± 0.26	875	0.29 ± 0.27	-0.02 (-0.04 to 0.01)	-0.03 (-0.05 to 0.00)
Rate of length gain, mm/day	786	0.37 ± 0.36	836	0.36 ± 0.39	872	0.35 ± 0.33	0.02 (-0.01 to 0.06)	0.01 (-0.02 to 0.05)
Adverse events, first 2 weeks of intervention	505	200 (27)	0.04	217 (2.0)	075			50(02) 05
Fever, no. (%)	785	209 (27)	836	217 (26)	8/5	269 (31)	-4.0 (-8.4 to 0.4)	-5.0 (-9.3 to -0.7)
Diarrhea, no. (%)	784	242 (31)	834	247 (30)	8/4	292 (33)	-2.0 (-6.5 to 2.5)	-3.0 (-7.4 to 1.4)
Eating, no. (%)	/84	113 (99)	836	819 (98)	8/3	828 (98)	1.0 (-0.2 to 2.2)	0.0 (-1.3 to 1.3)

¹Plus-minus values are means ± SD. Significance testing was performed for primary outcomes only. Malawi Developmental Assessment Tool and modified Willatts Problem Solving Assessment. Pairwise comparisons for continuous variables were performed with Student's t-test. Comparisons below P = 0.05 threshold are indicated with superscript letters with values shown in this legend. DHA-HO-RUTF, docosahexaenoic acid added to ready-to-use therapeutic food made with heigh-oleic acid peanuts; HO-RUTF, high-oleic acid ready-to-use therapeutic food; S-RUTF, standard ready-to-use therapeutic food.

[†] All values are differences with 95% confidence intervals unless otherwise noted.

[‡] This value is the odds ratio with 95% confidence interval. ^a P=0.044

 $^{b}P = 0.031$

 $^{c}P = 0.047$

 $^{d}P = 0.002$

31

Figure legends

Figure 1. CONSORT diagram of study participation.

Figure 2. Probability density plots of Malawi Developmental Assessment Tool global and domain z-scores of children receiving RUTF made with high oleic acid peanuts with added docosahexaenoic acid (DHA-HO-RUTF), RUTF made with oleic acid peanuts but without added DHA (HO-RUTF), or standard RUTF (S-RUTF). Probability densities were constructed using kernel density estimation. Global $n_{DHA-HO-RUTF} = 332$, $n_{HO-RUTF} = 312$, $n_{S-RUTF} = 342$. Gross motor domain $n_{DHA-HO-RUTF} = 331$, $n_{HO-RUTF} = 312$, $n_{S-RUTF} = 342$. Fine motor $n_{DHA-HO-RUTF} = 323$, $n_{HO-RUTF} = 331$, $n_{HO-RUTF} = 332$, $n_{HO-RUTF} = 331$, $n_{HO-RUTF} = 332$, $n_{HO-RUTF} = 342$.

Figure 3. Problem solving assessment intention scores of children receiving RUTF made with high oleic acid peanuts with added docosahexaenoic acid (DHA-HO-RUTF), RUTF made with oleic acid peanuts but without added DHA (HO-RUTF), or standard RUTF (S-RUTF). Percentages of children in each intervention group with each score are shown. Overall, children in each study food had similar intention scores in all three problems; the differences between food groups were not significant. The lowest and highest scores possible in each problem were the most common results among children with scores. Children with "No Score" were unable to engage in the task.

Figure 4. Box and whisker plot of plasma fatty acid content of 6 selected fatty acids in severely malnourished children receiving RUTF made with high oleic acid peanuts with added DHA (DHA-HO-RUTF), RUTF made with high oleic acid peanuts (HO-RUTF), or standard RUTF (S-RUTF). The boxes represent the interquartile range of the distribution with a heavy midline median value. The whiskers extend to 1.5 times the IQR, values outside of these designations are plotted as points. The statistical comparisons were made using a Wilcoxon Rank Sum test, the numbers of samples in each group were DHA-HO-RUTF=208 HO-RUTF=189 S-RUTF=162.









